HOME >> BIOLOGY >> NEWS
Orexigen reports positive phase II results for Excalia Combination-Therapy to treat obesity

San Diego, CA, 11:00 am EDT, October 22, 2006 OREXIGENTM Therapeutics, Inc., a privately held clinical-stage neuroscience company developing novel strategic approaches to the treatment of obesity, today announced that ExcaliaTM, a combination of two centrally-acting medications intended to provide and sustain clinically important weight loss, demonstrated significant weight loss in a six month, double-blind, phase IIa clinical study. The magnitude of weight reduction exceeded that seen with placebo. The findings showed that patients completing the blinded 24-week phase lost on average 9.2% of their weight from baseline using Excalia compared to an average of 0.4% weight loss from baseline for patients using placebo. The study results further demonstrate that weight loss continued through an additional 24 week open-label period achieving an average weight loss of 12% from baseline by 48 weeks. These top line phase IIa data for Excalia were presented at the annual meeting of the North American Association for the Study of Obesity (NAASO) in Boston.

"Excalia is designed to achieve an aggressive weight loss trajectory and then to delay the typical weight loss 'plateau' by offsetting one of the body's natural compensatory pathways. These phase II data suggest a level of efficacy that exceeded our expectations in relation to existing approaches," said Gary Tollefson, M.D., Ph.D., OREXIGEN president and CEO. "Excalia is designed to act on a specific reciprocally paired group of hypothalamic neurons that we believe will yield a clinically meaningful weight loss trajectory among significantly overweight individuals. We believe that these positive data support our theoretical approach."

Excalia is a proprietary combination of bupropion, a dopamine and norepinephrine reuptake inhibitor, plus zonisamide, an approved anticonvulsant medication. OREXIGEN's preclinical research suggests that combining these two central nervous system d
'"/>

Contact: Stephen Gendel
sgendel@biocompartners.com
212-918-4650
BioCom Partners
22-Oct-2006


Page: 1 2 3

Related biology news :

1. ChemGenex reports successful personalized dosing of Quinamed at ASCO
2. 1 month post launch, Interactive Autism Network reports 13,000 participants
3. Biosite reports on presentation of preliminary data from sepsis program
4. Biolex reports potential for more potent, efficacious antibodies in Nature Biotechnology
5. Dinosaurs climate shifted too, reports show
6. The New England Journal of Medicine reports data on eculizumab for the treatment of PNH
7. Portion distortion may contribute to expanding waistlines, study reports
8. Study reports findings on lung cancer death rates in never smokers
9. Breast implants not associated with cancer risk, study reports
10. Paper reports discovery of virus implicated in genetics of prostate cancer
11. First analysis of FDAs mifepristone adverse event reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2019)... ... February 01, 2019 , ... ... for Clinical Testing Laboratories by A2LA, which establishes requirements for medical laboratories to ... The laboratory is already CLIA-licensed as well as College of American Pathologists (CAP)-accredited, ...
(Date:1/25/2019)... ... January 24, 2019 , ... ... of its 2019 Association Industry Survey. The report indicates membership growth in some ... mid-November to early December 2018, received responses from over 500 association professionals across ...
(Date:1/21/2019)... ... ... Energetiq Technology, a world leader in high brightness broadband light sources, will ... Photonics West events taking place in San Francisco on February 1 – February 7, ... booth #941 at Photonics West. There will be live demonstrations of Energetiq’s ultra-bright broadband ...
Breaking Biology News(10 mins):
(Date:2/6/2019)... ... , ... Firmex announced today that VERTU Capital has partnered ... of the fastest-growing and most widely-used providers of virtual data rooms and secure ... provided by the Bank of Montreal. , Headquartered in Toronto, Canada, Firmex is ...
(Date:2/2/2019)... ... 31, 2019 , ... Signature Matrix and Signature Cord are ... applied stem cell research expert and Amazon best-selling author, Neil Riordan, PA, PhD, ... cord tissue allograft that originates from the same tissue used to manufacture the ...
(Date:1/30/2019)... SAN DIEGO (PRWEB) , ... January 29, 2019 ... ... fully integrated Contract Development and Manufacturing Organization (CDMO) serving the global biopharmaceutical and ... series A funding of $59.1 million backed by multiple global investors lead by ...
(Date:1/30/2019)... ... January 29, 2019 , ... K&R Negotiations announced today that Mladen Kresic, CEO ... event titled: Six Ways to Shorten the Sales Cycle : Reduce Complexity and ... the BrightTALK network. , Negotiation expert Kresic will discuss the realities of today’s ...
Breaking Biology Technology:
Cached News: